<DOC>
	<DOCNO>NCT00651027</DOCNO>
	<brief_summary>The metabolism PF-00868554 primarily mediate CYP3A , anticipate hepatic impairment modify PF-00868554 plasma concentration . Hence , important determine impact vary degree hepatic impairment pharmacokinetics , safety toleration 200 mg PF-00868554 administer single-dose .</brief_summary>
	<brief_title>Study To Assess The Impact Of Hepatic Impairment On The Safety , Tolerability And Pharmacokinetics Of Single-Dose 200 Mg Of PF-868554</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Male female subject nonchildbearing potential age 18 62 year age , inclusive ; Body Mass Index ( BMI ) approximately 18 35 kg/m2 ; total body weigh &gt; 50 kg ( 110 lb ) ; Subjects Class C classification ( Severe ChildPugh Scores great 10 ) ; Severe ascites and/or pleural effusion ; Had transplant kidney , heart liver ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>62 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>